Close Menu

equity investment

The collaboration will focus on the discovery, development, and commercialization of targeted immune evasion therapies for patients with cancer.

The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.

Including the new round, the maker of software to support precision oncology care and drug discovery has landed nearly $100 million in equity investments to date. 

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

Japanese software giant NEC invests in AI-centric software company BostonGene to advance immuno-oncology and other targeted cancer treatments.